BACKGROUND: Endothelial gene silencing via small interfering RNA (siRNA) transfection represents a promising strategy for the control of vascular disease. Here, we demonstrate endothelial gene silencing in human saphenous vein using three rapid siRNA transfection techniques amenable for use in the operating room. METHODS: Control siRNA, Cy5 siRNA, or siRNA targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or endothelial specific nitric oxide synthase (eNOS) were applied to surplus human saphenous vein for 10 minutes by (i) soaking, (ii) applying 300 mm Hg hyperbaric pressure, or (iii) 120 mm Hg luminal distending pressure. Transfected vein segments were maintained in organ culture. siRNA delivery and gene silencing were assessed by tissue layer using confocal microscopy and immunohistochemistry. RESULTS: Distending pressure transfection yielded the highest levels of endothelial siRNA delivery (22% pixels fluorescing) and gene silencing (60% GAPDH knockdown, 55% eNOS knockdown) as compared with hyperbaric (12% pixels fluorescing, 36% GAPDH knockdown, 30% eNOS knockdown) or non-pressurized transfections (10% pixels fluorescing, 30% GAPDH knockdown, 25% eNOS knockdown). Cumulative endothelial siRNA delivery (16% pixels fluorescing) and gene silencing (46% GAPDH knockdown) exceeded levels achieved in the media/adventitia (8% pixels fluorescing, 24% GAPDH knockdown) across all transfection methods. CONCLUSION: Endothelial gene silencing is possible within the time frame and conditions of surgical application without the use of transfection reagents. The high sensitivity of endothelial cells to siRNA transfection marks the endothelium as a promising target of gene therapy in vascular disease.
BACKGROUND: Endothelial gene silencing via small interfering RNA (siRNA) transfection represents a promising strategy for the control of vascular disease. Here, we demonstrate endothelial gene silencing in human saphenous vein using three rapid siRNA transfection techniques amenable for use in the operating room. METHODS: Control siRNA, Cy5 siRNA, or siRNA targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or endothelial specific nitric oxide synthase (eNOS) were applied to surplus human saphenous vein for 10 minutes by (i) soaking, (ii) applying 300 mm Hg hyperbaric pressure, or (iii) 120 mm Hg luminal distending pressure. Transfected vein segments were maintained in organ culture. siRNA delivery and gene silencing were assessed by tissue layer using confocal microscopy and immunohistochemistry. RESULTS: Distending pressure transfection yielded the highest levels of endothelial siRNA delivery (22% pixels fluorescing) and gene silencing (60% GAPDH knockdown, 55% eNOS knockdown) as compared with hyperbaric (12% pixels fluorescing, 36% GAPDH knockdown, 30% eNOS knockdown) or non-pressurized transfections (10% pixels fluorescing, 30% GAPDH knockdown, 25% eNOS knockdown). Cumulative endothelial siRNA delivery (16% pixels fluorescing) and gene silencing (46% GAPDH knockdown) exceeded levels achieved in the media/adventitia (8% pixels fluorescing, 24% GAPDH knockdown) across all transfection methods. CONCLUSION: Endothelial gene silencing is possible within the time frame and conditions of surgical application without the use of transfection reagents. The high sensitivity of endothelial cells to siRNA transfection marks the endothelium as a promising target of gene therapy in vascular disease.
Authors: Nicholas D Andersen; Thomas S Monahan; Junaid Y Malek; Monica Jain; Soizic Daniel; Lena D Caron; Leena Pradhan; Christiane Ferran; Frank W Logerfo Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Vincent E Friedewald; Thomas D Giles; James L Pool; Clyde W Yancy; William C Roberts Journal: Am J Cardiol Date: 2008-08-15 Impact factor: 2.778
Authors: M J Mann; G H Gibbons; H Hutchinson; R S Poston; E G Hoyt; R C Robbins; V J Dzau Journal: Proc Natl Acad Sci U S A Date: 1999-05-25 Impact factor: 11.205
Authors: M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau Journal: Lancet Date: 1999-10-30 Impact factor: 79.321
Authors: Gabriele Dorn; Sadhana Patel; Glen Wotherspoon; Maja Hemmings-Mieszczak; Jane Barclay; Francois J C Natt; Pierre Martin; Stuart Bevan; Alyson Fox; Pam Ganju; William Wishart; Jonathan Hall Journal: Nucleic Acids Res Date: 2004-03-16 Impact factor: 16.971
Authors: Christoph S Nabzdyk; Maggie C Chun; Hunter S Oliver-Allen; Saif G Pathan; Matthew D Phaneuf; Jin-Oh You; Leena K Pradhan-Nabzdyk; Frank W LoGerfo Journal: Biomaterials Date: 2014-01-04 Impact factor: 12.479
Authors: Thomas C F Bodewes; Joel M Johnson; Michael Auster; Cindy Huynh; Sriya Muralidharan; Mauricio Contreras; Frank W LoGerfo; Leena Pradhan-Nabzdyk Journal: FASEB J Date: 2016-09-26 Impact factor: 5.191